A common retrovirus encases itself in an extracellular matrix, enabling its transfer between T4 cells. The discovery of this new mode of infectivity has the potential to lead to new ways to combat the virus, human T cell leukemia virus type 1 (HTLV-1), which is associated with cancers and inflammatory disorders (pages 83-89).
The interactions between a virus and its host are a continual game of cat and mouse. The hosts have developed a variety of mechanisms to block viral infection and persistence, including physical barriers to entry, intracellular proteins that interfere with viral infection and the innate and adaptive immune responses. Viruses have evolved a number of strategies to counteract and evade host cellular defenses. They encode proteins that inhibit antiviral proteins and have developed various mechanisms to escape surveillance by the immune system.
In the current issue of Nature Medicine, PaisCorreia et al. 1 uncover a previously unknown mechanism for viral transmission and persistence. They study a virus associated with cancer and inflammatory disorders, HTLV-1, and find that after budding from the membrane of infected CD4 + T cells, viral particles remain associated with the cell, transiently stored in protective extracellular microenvironments. During interactions between T cells, these structures are transferred from infected to uninfected cells, ultimately resulting in the infection of the target cell. The study provides evidence for a role of the extracellular matrix in viral transmission.
HTLV-1 infects approximately 20 million individuals worldwide 2 and is spread from person to person primarily by infected cells in breast milk, blood and semen 3 . In approximately five percent of infected individuals, HTLV-1 is associated with disease: adult T cell leukemia, a CD4 + T cell malignancy, or one of several inflammatory disorders including HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP) 3 .
Soon after the discovery of the virus 4 , it was observed that, unlike HIV and most other retroviruses, HTLV-1 nearly always requires cell-to-cell interactions for transmission and infection; it is poorly infectious as a cell-free viral particle. Infection rates after blood transfusions indicated that HTLV-1 transmission requires passage of infected cells 5 , and, in cell culture, cell-free viral particles cannot routinely infect primary CD4 + T lymphocytes, the natural targets of HTLV-1. Although it is known that HTLV infection requires cell-tocell contact, the precise interactions between cells required for the infection of the target have not been well characterized.
Pais-Correia et al. 1 began their studies by performing confocal and electron microscopy analyses of HTLV-1-infected CD4 + T cells. They examined cells isolated from HTLV-1-infected individuals, as well as transformed cell lines chronically infected with HTLV-1, and observed assemblies of mature viral particles on the surface of infected cells 1 (Fig.  1) . Characterization of these viral assemblies showed that they were enriched in specific components of the extracellular matrix and cellular linker proteins. Direct comparison of infected and uninfected CD4 + T cells showed that expression of HTLV-1 increased the expression of these specific proteins on the cell surface and resulted in their redistribution to the extracellular viral assemblies.
Further studies revealed that the extracellular viral assemblies have a key role in ushering HTLV-1 to neighboring T cells. The researchers exposed CD4 + T cells from HTLV-1-infected individuals to CD4 + T cells from uninfected individuals and observed that the virus quickly moved to multiple places on the surface of the target cells, including points distal to the point of cell-to-cell contact 1 . Extracellular matrix components colocalized with viral proteins, indicating that the HTLV-1 was being transferred in the context of the viral assemblies. The authors then showed that the structures they observed by microscopy were important for infection; removing these structures from HTLV-1-infected cells, although not affecting the ability of the infected cells to make contacts with uninfected T cells, dramatically reduced their ability to infected target cells.
Previous work, originally by Ikagura et al. 4 , indicated that HTLV-1 can spread between T cells by forming a supramolecular structure, termed a virological synapse. They observed HTLV-1 core proteins and RNA genome in infected cells at the point of contact with uninfected cells, along with local reorganization of cellular components, followed by the appearance of virus inside the target cell 4 . These observations, along with later work, supported the notion that HTLV-1-infected cells polarize after contact between the T cells and that the virus buds into closed synaptic clefts before binding and infecting target cells 6 .
In contrast, Pais-Correia et al. 1 observed the rapid transfer of fully formed HTLV-1 particles stored (and protected) on the surface of infected cells to target cells in a manner that does not appear to involve synaptic clefts or cytoskeletal rearrangements. It is not yet clear whether the two groups were observing similar phenomena under different conditions or two distinct methods of transmission.
Many retroviruses, including HTLV-1 and HIV, infect cells of the immune system, and the immune response involves multiple interactions between cells. Although the use n e w s a n d v i e w s of cell-to-cell interactions during transmission was originally believed to distinguish HTLV from other retroviruses, later studies indicated that transmission of several other retroviruses is two to three orders of magnitude more efficient when cells physically interact. Virological synapses play a part in HIV transmission from dendritic cells (DCs) and macrophages to CD4 + T cells 7, 8 as well as between T cells 9 .
More recently, transmission of retroviruses between cells has also been observed to occur along filopodial membrane bridges 10 and via thinner membrane extensions called nanotubes 11 . Nanotubes also seem to mediate the transmission of HTLV-1 (N. Van Prooyen and G. Franchini, US National Cancer Institute, personal communication). More studies will be needed to clarify how the transfer of viral assemblies is related to the previously described methods of cell-to-cell transmission.
The discovery of Pais-Correia et al. 1 further supports the notion that, in vivo, retroviruses exploit interactions between immune cells to facilitate their spread. At first glance, viral spread by extracellular assemblies seems to be most similar to HIV transmission from DCs and macrophages, where viruses assembled on the cell surface are stored in large invaginations and then mobilized to sites of cell-tocell contact for subsequent transmission. DCs are known to also facilitate HTLV-1 transmission; infected DCs can rapidly pass HTLV-1 to CD4 + T cells, resulting in efficient infection 12 . Electron microscopy analysis of HTLV-1-infected DCs have revealed the presence of multiple virions associated with the cell surface of DCs (K.S. Jones, G. Franchini and F.W. Ruscetti, unpublished data), suggesting that extracellular viral assemblies are involved in DC-to-T-cell transmission, as well as between T cells.
Why have HTLV-1 and other viruses evolved to use cell-to-cell transmission? One reason might be efficiency: the mechanism eliminates the step of viral diffusion before attachment and entry. This would be particularly crucial for HTLV-1, which is produced at low levels by infected T cells and is very inefficient at productively infecting CD4 + T cells as a cell-free viral particle. Cellto-cell transmission could also help in viral persistence, by allowing the virus to avoid neutralization by antibodies; perhaps the extracellular matrix cocoons the viral particles, protecting them from physical shearing as well as from neutralization by antibodies. This effect would be analogous to bacterial biofilms, where a bacterially produced polysaccharide matrix can confer resistance to antibiotics.
For HTLV-1, whose envelope proteins are highly conserved and poorly glycosylated, these protective structures would seem to be particularly important. Such protective structures may also explain the persistence of high numbers of HTLV-1-infected cells in individuals with HAM-TSP, who have high levels of neutralizing antibodies.
A number of viruses other than retroviruses have also been shown to be transmitted cell to cell, to be poorly infectious as cell-free particles or to have substantial viral loads in the presence of neutralizing antibodies. It seems possible that some of these viruses may also form extracellular viral assemblies on infected cells.
The discovery of these viral assemblies suggests possible future therapeutic avenues for treatment of the HAM-TSP, a disease that progresses more rapidly in the presence of high amounts of HTLV-1. Agents that disrupt the assemblies may lower virus levels, either directly by decreasing viral transmission or indirectly by making the virus more susceptible to immune clearance. Such compounds might target the interactions between the extracellular matrix, linker proteins and carbohydrate moieties that ensure the cohesiveness of the biofilm. Such drugs could turn out to be the elusive 'better mousetrap' in the fight against HTLV-1 infection. Hypertension is the most common disease in humans, affecting over one billion people worldwide, and it is a major treatable risk factor in cardiovascular diseases such as stroke, myocardial infarction and kidney failure [1] [2] [3] . Despite the importance of hypertension as a cause of cardiovascular disease, its pathogenesis is largely unknown. But there is ample evidence supporting Arthur Guyton's 30-year-old hypothesis that blood pressure depends on salt handling by the kidney 1 . As the kidney has a major role in maintaining salt balance, understanding the mechanisms that regulate the renal handling of salt is crucial to the prevention and treatment of hypertension. Molecular and genetic approaches have defined key players and molecular pathways that determine variations in blood pressure. We know the identity of the major sodium transporters-the furosemide, thiazide and amiloride receptors-expressed in the distal nephron 2 . Aldosterone, secreted by the adrenal gland, is the key hormone that controls epithelial Na + channel activity in the aldosterone-sensitive distal nephron, thereby controlling sodium balance, blood volume and blood pressure 3 . The renin-angiotensinaldosterone system (RAAS) (Fig. 1a) exerts, in turn, the main physiological control over aldosterone secretion. Interestingly, all genetic diseases that affect blood pressure in humans map to the RAAS, involving genes expressed either in the adrenal gland or in the kidney, stressing the importance of this system as a cause of hypertension 2, 3 .
RAAS function and blood pressure control are circadian. Early during the night, blood pressure typically drops to its lowest values ('dip') to raise the next morning to its highest level ('surge'). The circadian rhythm of blood pressure is clinically relevantindividuals who have an excessive morning surge or who lack the nocturnal dip tend to show worse cardiovascular outcomes 4 . In humans, baseline hormone peak times start with melatonin near the middle of the sleep period, followed by renin, aldosterone and then cortisol around wake time 5 . In mice and rats, circadian rhythms of plasma renin, aldosterone and corticosterone concentrations have also been documented 6 . The biosynthesis of aldosterone (Fig. 1b ) takes place specifically in the outermost layer of the adrenal cortex-the zona glomerulosa. This layer-specific synthesis is insured by cell-specific expression of the key enzyme for aldosterone biosynthesis-CYP11B2, also known as aldosterone synthase. So far, the prevailing idea is that CYP11B2 is the only molecule crucial for aldosterone production in the zona glomerulosa.
In this issue of Nature Medicine, Doi et al. 7 provide strong evidence for another enzyme-hydroxy-∆ 5 -steroid dehydrogenase, 3β-and steroid ∆-isomerase-6 (HSD3b6)-as having an equally crucial role in aldosterone biosynthesis.
The authors found that disruption of the two cryptochrome genes Cry1 and Cry2-core elements of the circadian clock-leads to salt-dependent hypertension 7 . In wildtype mice, the plasma concentration of aldosterone oscillates by about fourfold during the day-night cycle. Upon Cry1 and Cry2 gene inactivation, aldosterone plasma concentrations were markedly and constituvely elevated in the mice. Moreover, the control of blood pressure was severely impaired in the mutant mice; they became 'nondippers' and were exquisitely susceptible to developing hypertension upon increased salt intake. Treatment with the aldosterone antagonist eplirenone restored blood pressure to normal values.
The team went on to identify Hsd3b6 as the target of the cryptochromes responsible for this effect on blood pressure 7 . This enzyme catalyzes the conversion of ∆ 5 -3β-hydroxysteroids into ∆ 4 -3-ketosteroids, an enzymatic reaction required for aldosterone biosynthesis (Fig. 1b) . Crucially, they found that this enzyme is selectively expressed in the aldosterone-producing zona glomerulosa of the adrenal gland 7 .
These results may have major implications for human hypertension. For example, the aldosterone-synthesis pathway that Doi et al. 7 defined in the mouse may exist in human adrenals, as HSD3B1 (the human ortholog of Hsd3b6) is also selectively expressed in the zona glomerulosa. If this pathway is indeed relevant to humans and this gene becomes a new candidate risk factor for the genesis of hypertension, it would be interesting to determine whether common gene polymorphisms linked to increased HSD3B1 activity may be identified in subject cohorts with the nondipping and salt-sensitive forms of hypertension. In fact, rare mutations with large effects on blood pressure, which could be identified in large cohorts of individuals with hypertension 8 , may even exist.
The results of this study also mean that HSD3B1 may be a new target for the development of antihypertensive drugs. So far, efforts have focused on developing new antagonists of CYP11B2, the canonical key enzyme for aldosterone biosynthesis 9, 10 . A specific HSD3B1 inhibitor would open the possibility of a sequential and synergistic
